- The journal
- Air Jordan 1 Retro High Top 3
- el producto platform puma Turino Stacked EU 41 platform puma Black Rosewater
- Donald, Wears Large Shoe Size, Barron Trump Is Taller Than Melania, Puma Cali Sport chunky sneakers in white and black
- air jordan 1 royal nike outlet
- Giuseppe Zanotti low top embossed croc-effect sneakers
- Gnarhunters Nike SB Dunk Low DH7756 010 Release Date On Foot
- Air Jordan 1 Stage Haze Release Date 555088 108 1
- nike dunk low university blue
- Air Jordan 5 Racer Blue CT4838 004 Release Date Price 4
- buy air jordan 1 twist panda cd0461 007 store list
- Aims & Scope
- Editorial Policies and Processes
- Scientific and Methodological Rigor
- Production and Administration
- Committees
- Authors
- Ethical Considerations
- Submit Article
- Archive
- Indexation
- Search
- Contact us
Farm Comunitarios. 2018 Mar 30;10(1):47-49. doi: 10.5672/FC.2173-9218.(2018/Vol10).001.07
Possible link of loratadine with a fatal outcome in an at-risk patient
Pol E, Mirch R, Mayoral E, Martínez P. Possible link of loratadine with a fatal outcome in an at-risk patient. Farm Comunitarios. 2018 Mar 30;10(1):47-49. doi: 10.5672/FC.2173-9218.(2018/Vol10).001.07
Abstract :
A 69-year-old man, who has been clinically chronic for severe and persistent mental illness, COPD, diabetes and hypothyroidism, stabilized for several months, began treatment with loratadine for rhinitis. The next day he is found unconscious and rushed to the general hospital for intensive care, where he dies a day later. The case analysis reveals a possible “butterfly effect,” a fatal outcome caused by a low-risk drug, given the “borderline” situation of prior therapy.
Keywords :
Loratadine, ventricular arrhythmias, death, mental illness, butterfly effect
Editor: © SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria.
Copyright© SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit
https://creativecommons.org/licenses/by-nc/4.0/deed.en
-
Manual for authors
Journal Information
Last update of farmaceuticoscomunitarios.org : 29.03.2018
Copyright © (Sociedad Española de Farmacia Clínica, Familiar y Comunitaria) |
ISSN Digital edition: 2173-9218
Journal committees - Legal notice - Privacy policy - Cookies policy - Advertising policy
e-mail: webmaster@farmaceuticoscomunitarios.org | Responsible for this web site: Jordi Serrano Valdés
Development, Web design & computer programming: Edittec |
The information provided on this site is intended to complement and not to replace the
relation between a patient and his or her existing physician.
